Xintela AB AI Stock Analysis
Want to see SE:XINT full AI Analyst Report?
Xintela AB (XINT) AI Stock Analysis
Xintela AB
(Nasdaq OMX AB:XINT)
The score is primarily weighed down by very large operating losses, substantial ongoing cash burn, and negative equity alongside debt, which together raise financing and dilution risk. Technicals are mixed (below key longer-term averages with negative MACD), and valuation signals are limited because the company is loss-making and has no provided dividend yield.
Xintela AB (XINT) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 120.15M
- Dividend Yield
- ―
- Average Volume (3M)
- 233.29K
- Price to Earnings (P/E)
- -2.4
- Beta (1Y)
- 0.36
- Revenue Growth
- -38.46%
- EPS Growth
- 9.02%
- Country
- Sweden
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Xintela AB Business Overview & Revenue Model
Company Description
Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XIN...
How the Company Makes Money
Xintela’s monetization is primarily intended to come from advancing its ITGA10-based programs and capturing value through partnering and commercialization. Key expected revenue streams include: (1) out-licensing or co-development deals for its drug a...
Xintela AB Financial Statement Overview
Summary
Revenue is growing (TTM 3.03M, +17.2%) with a strong gross margin (~82%), but the business remains severely unprofitable (TTM net loss -47.7M; net margin ~-1,575%) with heavy cash burn (TTM OCF -47.4M; FCF -38.3%). Balance sheet risk is elevated with negative equity (-27.2M) alongside meaningful debt (30.0M), increasing financing/dilution risk.
Income Statement
18Very NegativeBalance Sheet
22NegativeCash Flow
16Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.03M | 2.28M | 4.21M | 78.00K | 0 | 0 |
| Gross Profit | 2.50M | 1.68M | 4.21M | 78.00K | -3.79M | -3.50M |
| EBITDA | -45.47M | -46.08M | -38.90M | -53.47M | -64.83M | -57.18M |
| Net Income | -47.72M | -48.56M | -39.19M | -54.08M | -66.22M | -58.93M |
Balance Sheet | ||||||
| Total Assets | 35.10M | 29.02M | 24.80M | 18.39M | 24.52M | 24.74M |
| Cash, Cash Equivalents and Short-Term Investments | 30.72M | 23.21M | 16.68M | 7.81M | 8.34M | 9.94M |
| Total Debt | 30.00M | 20.00M | 0 | 0 | 0 | 0 |
| Total Liabilities | 62.33M | 34.30M | 30.75M | 14.02M | 18.74M | 20.80M |
| Stockholders Equity | -27.23M | -5.27M | -5.95M | 4.38M | 5.78M | 3.95M |
Cash Flow | ||||||
| Free Cash Flow | -38.28M | -41.62M | -40.70M | -53.22M | -39.60M | -44.15M |
| Operating Cash Flow | -47.42M | -41.62M | -40.70M | -53.12M | -39.49M | -42.89M |
| Investing Cash Flow | 70.00K | 0 | 0 | -104.00K | -27.52M | -1.20M |
| Financing Cash Flow | 68.40M | 48.53M | 50.09M | 51.79M | 64.56M | 20.43M |
Xintela AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XINT, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.16, and below the 200-day MA of 0.21, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 34.83 is Neutral, neither overbought nor oversold. The STOCH value of 23.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XINT.
Xintela AB Peers Comparison
Overall Rating
SE:ISOFOL48Neutral
SE:ELIC47Neutral
SE:NXTCL46Neutral
SE:XBRANE46Neutral
SE:ACTI44Neutral
SE:XINT42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | SEK 339.08M | -5.64 | -58.68% | ― | ― | 35.02% | |
| 47Neutral | SEK 166.84M | -7.07 | -56.09% | ― | ― | 14.10% | |
| 46Neutral | SEK 28.63M | -0.59 | -81.23% | ― | -4.02% | 35.86% | |
| 46Neutral | SEK 219.45M | -5.89 | -11.52% | ― | -38.80% | -120.18% | |
| 44Neutral | SEK 92.53M | -5.01 | -85.07% | ― | ― | 51.09% | |
| 42Neutral | SEK 120.15M | -2.38 | 245.07% | ― | -38.46% | 9.02% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:XINT | Xintela AB | 0.14 | -0.12 | -46.54% | |
| SE:XBRANE | Xbrane Biopharma AB | 10.65 | 0.70 | 6.98% | |
| SE:ISOFOL | Isofol Medical AB | 1.06 | 0.36 | 51.36% | |
| SE:ELIC | Elicera Therapeutics AB | 2.50 | -2.78 | -52.66% | |
| SE:ACTI | Active Biotech AB | 3.51 | -2.60 | -42.54% | |
| SE:NXTCL | NextCell Pharma AB | 0.23 | -0.56 | -71.25% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 25, 2026
